We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

187 hedge funds and large institutions have $557M invested in Portola Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 67 increasing their positions, 55 reducing their positions, and 67 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 55

17% less funds holding

Funds holding: 224187 (-37)

49% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 67

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

70% less capital invested

Capital invested by funds: $1.88B → $557M (-$1.32B)

75% less call options, than puts

Call options by funds: $2.4M | Put options by funds: $9.78M

Holders
187
Holders Change
-37
Holders Change %
-16.52%
% of All Funds
4.12%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
34
Increased
67
Reduced
55
Closed
67
Calls
$2.4M
Puts
$9.78M
Net Calls
-$7.37M
Net Calls Change
-$943K
Name Holding Trade Value Shares
Change
Change in
Stake
TC
226
TwinBeech Capital
New York
-$366K -15,312 Closed
FRM
227
Fox Run Management
Connecticut
-$358K -15,010 Closed
Hudson Bay Capital Management
228
Hudson Bay Capital Management
Connecticut
-$340K -14,240 Closed
Qube Research & Technologies (QRT)
229
Qube Research & Technologies (QRT)
United Kingdom
-$335K -14,023 Closed
CIBC Private Wealth Group
230
CIBC Private Wealth Group
Georgia
-$300K -12,573 Closed
WG
231
Welch Group
Alabama
-$299K -12,500 Closed
Jennison Associates
232
Jennison Associates
New York
-$277K -11,588 Closed
BCM
233
Bayesian Capital Management
New York
-$268K -11,222 Closed
BAM
234
Blueshift Asset Management
New Jersey
-$267K -11,164 Closed
Mariner
235
Mariner
Kansas
-$241K -10,073 Closed
ECM
236
ExodusPoint Capital Management
New York
-$222K -9,288 Closed
SC
237
Scotia Capital
Ontario, Canada
-$212K -8,875 Closed
AI
238
Atria Investments
North Carolina
-$209K -8,772 Closed
AAMU
239
Amundi Asset Management US
Massachusetts
-$167K -7,000 Closed
PA
240
Parallel Advisors
California
-$132K -5,536 Closed
QI
241
QS Investors
New York
-$95K -4,000 Closed
QT
242
Quantbot Technologies
New York
-$28.5K -2,283 -99%
NIT
243
NumerixS Investment Technologies
British Columbia, Canada
-$31K -1,300 Closed
Lazard Asset Management
244
Lazard Asset Management
New York
-$22K -923 Closed
TRCT
245
Tower Research Capital (TRC)
New York
-$19K -801 Closed
AP
246
Atwood & Palmer
Missouri
-$12K -500 Closed
HRC
247
Hoertkorn Richard Charles
-$12K -500 Closed
CP
248
Corbenic Partners
Pennsylvania
-$1.04K -83 -73%
SFS
249
Sowell Financial Services
Arkansas
-$487 -39 -39%
CFN
250
Cordasco Financial Network
Florida
+$624 +50 New

PTLA Hedge Fund Activity: Q1 2020 in Review

187 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q1 2020, worth a combined $557M — down 70% from $1.88B a quarter earlier.

Sellers outnumbered buyers: 67 funds closed out of PTLA and 34 opened new positions — a net loss of 33 holders — while 55 trimmed existing stakes and 67 added.

The largest buyer was William Blair Investment Management, adding an estimated $34.3M. The largest seller was Franklin Resources, exiting entirely with an estimated $32.9M sold.

  • 187 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q1 2020, down from 224 in Q4 2019.
  • Funds reported $557M of Portola Pharmaceuticals, Inc. stock for Q1 2020, down 70% quarter-over-quarter.
  • 34 funds opened new Portola Pharmaceuticals, Inc. positions in Q1 2020 and 67 closed out, a net change of -33 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q1 2020 was William Blair Investment Management, an estimated $34.3M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q1 2020 was Franklin Resources, an estimated $32.9M sold.

Based on aggregated 13F filings for Q1 2020.